CG Oncology, based in Irvine, Calif., was founded in 2010 by CEO Arthur Kuan. The company, which was last valued at $405 million in September 2022, is a developer of genetically engineered oncolytic immunotherapy treatments for individuals with advanced cancer.
Last September, the company announced an oversubscribed $120 million Series E funding round led by ORI Capital, Longitude Capital and Decheng Capital. The company said it will use the new capital to advance its lead programs toward FDA review and broaden its drug pipeline to address other unmet needs in urologic cancer. Its lead drug candidate, CG0070, has reached Phase 3 testing as a monotherapy for non-muscle invasive bladder cancer.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/02/2023 | Series F | $105.02MM | $xx.xx | $615.24MM | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
81,587,937
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management
|
||||||
09/30/2022 | Series E | $120MM | $xx.xx | $405.38MM | Decheng Capital, Palm Drive Capital | |
Price per Share
$xx.xx
Shares Outstanding
112,422,700
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Decheng Capital, Palm Drive Capital
|
||||||
12/10/2020 | Series D | $47.3MM | $xx.xx | $212.97MM | Kissei Pharmaceutical, ORI Healthcare Fund, Camford Capital, Perservance Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
53,271,754
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Kissei Pharmaceutical, ORI Healthcare Fund, Camford Capital, Perservance Capital Management
|
||||||
03/18/2019 | Series C | $22MM | $xx.xx | $54.19MM | ORI Healthcare Fund, Perserverance Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
73,598,283
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
ORI Healthcare Fund, Perserverance Capital Management
|
||||||
08/05/2015 | Series B | $10MM | $xx.xx | $31.64MM | Ally Bridge Group, WI Harper Group, Whitesun Healthcare Ventures, Song Hong Fang | |
Price per Share
$xx.xx
Shares Outstanding
11,973,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ally Bridge Group, WI Harper Group, Whitesun Healthcare Ventures, Song Hong Fang
|
||||||
07/28/2014 | Series A-1 | $3.57MM | $xx.xx | $11.9MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,075,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3.0
Key Investors
Undisclosed Investors
|